Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes

COMMENTED

Diabetes - General

Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus

Ann Intern Med.

Roglic G, Norris SL

doi: 10.7326/M18-1149.

COMMENTED

Type 2 DiabetesGlycemic Control

Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes

Diabetes Care.

Yaron M, Roitman E, Aharon-Hananel G, Landau Z, Ganz T, Yanuv I, Rozenberg A, Karp M, Ish-Shalom M, Singer J, Wainstein J, Raz I

doi: 10.2337/dc18-0166.

COMMENTED

Glycemic Control

Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study

Diabetes Care.

Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG

doi: 10.2337/dc18-0287.

COMMENTED

Diabetes - GeneralType 2 DiabetesGlycemic Control

The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (the Diabetes & Aging Study)

Diabetes Care.

Vaisar T, Durbin-Johnson B, Whitlock K, Babenko I, Mehrotra R, Rocke DM, Afkarian M

doi: 10.2337/dc18-0699.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Diabetes Care.

Jabbour SA, Frìas JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C

doi: 10.2337/dc18-0680.

Type 2 DiabetesGlycemic Control

Durability of Glycemic Control with Dapagliflozin, an SGLT2 Inhibitor, Compared with Saxagliptin, a DPP4 Inhibitor, in Patients with Inadequately Controlled Type 2 Diabetes

Diabetes Obes Metab.

Bailey CJ, Del Prato S, Wei C, Reyner D, Saraiva G

doi: 10.1111/dom.13841.

COMMENTED

Type 2 DiabetesGlycemic Control

The Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A_1c in the ADVANCE Trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

doi: 10.2337/dc19-1817.

Diabetes - GeneralType 1 DiabetesType 2 DiabetesGlycemic Control

Baseline Glycated Hemoglobin Values Predict the Magnitude of Glycemic Improvement in Patients with Type 1 and Type 2 Diabetes: Subgroup Analyses from the DIAMOND Study Program

Diabetes Technol Ther.

Billings LK, Parkin CG, Price D

doi: 10.1089/dia.2018.0163.

Diabetes - GeneralType 2 Diabetes

Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial

Diabetes Care.

Basu S, Raghavan S, Wexler DJ, Berkowitz SA

doi: 10.2337/dc17-2252.

Related content

Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes

Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study

The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (the Diabetes & Aging Study)

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Durability of Glycemic Control with Dapagliflozin, an SGLT2 Inhibitor, Compared with Saxagliptin, a DPP4 Inhibitor, in Patients with Inadequately Controlled Type 2 Diabetes

The Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial

Baseline Glycated Hemoglobin Values Predict the Magnitude of Glycemic Improvement in Patients with Type 1 and Type 2 Diabetes: Subgroup Analyses from the DIAMOND Study Program

Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial

The Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A_1c in the ADVANCE Trial